Effects of valproate on serotonin-induced intracellular calcium mobilization in human platelets

Tatsuyuki Akimoto, MD, PhD; Ichiro Kusumi, MD, PhD; Katsuji Suzuki, MD, PhD; Takuya Masui, MD; Tsukasa Koyama, MD, PhD

Aim: Valproate (VPA) is effectively used in the treatment of bipolar disorder, although the mechanism of action is unclear. In patients with bipolar disorder, serotonin 5-hydroxytryptamine (5-HT)–induced intraplatelet calcium (Ca) mobilization has been shown to be enhanced.

Methods: We examined the effect of VPA on 5-HT–induced Ca response in the platelets of normal subjects, in the presence of a calmodulin antagonist W-7 (N-[6-aminohexyl]-5-chloro-1-naphthalenesulfonamide), a protein kinase C (PKC) activator phorbol 12-myristate 13-acetate (PMA) or PKC inhibitors staurosporine and bisindolylmaleimide II. Results: VPA inhibited the 5-HT–induced Ca response in a concentration-dependent manner. For calmodulin pathways, W-7 enhanced the 5-HT–stimulated Ca response, which was not affected by VPA. For PKC pathways, PMA reduced the Ca response, although both PKC inhibitors had no effect. PMA, staurosporine or bisindolylmaleimide II reversed the inhibitory effect of VPA on the Ca response, while W-7 did not modify it. Conclusion: These findings suggest the possibility that the mechanism of action of VPA may be partly related to PKC signalling.

Introduction

Recent studies have suggested that abnormalities in intracellular signal transduction processes may be important in the etiology of bipolar disorder and that mood stabilizers such as lithium and valproate (VPA) have common effects on postreceptor functions, which may be responsible for mood stabilizing mechanisms. Probably reflecting postreceptor signal transduction changes, it has been repeatedly observed that serotonin 5-hydroxytryptamine (5-HT)–induced intraplatelet calcium (Ca) mobilization is enhanced in bipolar disorder. In recent years, VPA has been demonstrated to possess antimanic properties which, in the treatment of bipolar disorders, are obtained several days after VPA administration. VPA has acute effects on inhibitory and excitatory amino acid systems and plasma membrane ion channels in the central nervous system.
myosin light chain kinase, Ca/calmodulin-dependent enzyme, involved in the 5-HT–induced intraplatelet Ca response in a concentration-dependent manner and exerted its effect for a short time (30 min). However, the mechanism of VPA rapid inhibitory effect on the 5-HT–induced Ca response has still been unclear. In this pilot study, to elucidate whether the effect of VPA on intracellular Ca mobilization is involved in calmodulin and PKC systems, we investigated the effect of VPA on 5-HT–induced Ca response in the presence of a calmodulin antagonist or PKC modulators in the platelets of healthy subjects.

Methods

We purchased 5-hydroxytryptamine (HT) creatinine sulfate N-(6-aminohexyl)-5-chloro-1-naphthalensulfonamide (W-7), phorbol 12-myristate 13-acetate (PMA) and bisindolylmaleimide II from Sigma Chemical Co. (St. Louis, Mo.). Sodium valproate was kindly provided by Kyowa Hakko Kogyo Co. (Tokyo, Japan), and we purchased furatoxymethyl ester for 15 minutes at 37°C. Further incubation was then performed with 4 µM furatoxymethyl ester for 15 minutes. Platelets were isolated from the PRP by further centrifugation at 600 ×g for 10 minutes at room temperature. The PRP was divided into 4 or 5 aliquots and was incubated without VPA, or with one of 3 or 4 concentrations of VPA for 15 minutes at 37°C. Further incubation was then performed with 4 µM furatoxymethyl ester for 15 minutes. Platelets were isolated from the PRP by further centrifugation at 600 ×g for 15 minutes. The platelet pellet was suspended in Krebs-Ringer HEPES buffer (145 mM NaCl, 5 mM KCl, 1 mM MgSO4, 0.5 mM Na2HPO4, 6 mM glucose, 10 mM HEPES, pH 7.4). After 1 mM CaCl2 was added to the suspended platelets, they were prewarmed in a cuvette at 37°C for 4 minutes with or without a calmodulin antagonist W-7 (30 µM), a PKC activator PMA (1 nM), and PKC inhibitors staurosporine (10 nM) or bisindolylmaleimide II (500 nM). Ten µM 5-HT was added to the incubation medium, and fluorescence was measured on a Hitachi F-2000 fluorometer with excitation at 340 and 380 nm and with emission at 510 nm using a Ca2+-dye dissociation constant (Kd) of 224 nM. Intracellular Ca concentrations were calculated from the ratio of fluorescence intensities at 2 excitation wavelengths in the platelet samples, according to the method of Grynkiewicz and colleagues. Ca increase represents that initial peak minus resting level.

Statistics

Data are expressed as the mean (and standard error of the mean [SEM]). The effect of VPA concentrations on basal Ca level and 5-HT–induced Ca response were analyzed with a 1-way analysis of variance (ANOVA) for repeated-measures, followed by post-hoc Dunnett’s test. The effects of VPA and calmodulin/PKC modulators on 5-HT–induced Ca response were examined with a 2-way ANOVA for repeated-measures. The sphericity assumption of the covariance matrix was tested to examine whether a within-subjects test could be valid. When there was a significant interaction between the effect of VPA and the presence of a calmodulin/PKC modulator, a 1-way ANOVA was used to examine the dose-dependent effect of VPA on the percent inhibition of Ca response by a calmodulin/PKC modulator. Significant differences among VPA concentrations were analyzed with post-hoc Dunnett’s test. A paired t test was used to assess the effect of calmodulin/PKC modulators on the 5-HT–induced Ca response in the absence of VPA.
Results

Effects of VPA (10–1000 µg/mL) on the 5-HT (10 µM)-induced Ca response were shown in Table 1. Although basal Ca concentration was unchanged, VPA significantly reduced the 5-HT–induced Ca response in a concentration-dependent manner (F4,48 = 64.424, p < 0.0001, n = 13, p < 0.05 for 50 µg/mL, 88.2% of control; p < 0.01 for 100 µg/mL, 80.4% of control; p < 0.01 for 1000 µg/mL, 40.7% of control).

Effects of VPA on 5-HT–induced Ca response in the presence of a calmodulin antagonist

In the absence of VPA, the 5-HT–induced Ca response pretreated with 30 µM W-7 was significantly enhanced, up to 147.8%, compared with the response without W-7 (Fig. 1; t [df 3] = 3.391, p < 0.05, n = 4). The enhanced effect of W-7 on the Ca response was not affected by VPA (10–100 µg/mL); that is, there was no significant interaction between the effect of VPA and the presence of W-7 (F3,12 = 0.155, p = 0.929, n = 4).

Effects of VPA on 5-HT–induced Ca response with a PKC stimulator

The pretreatment with 1 nM PMA significantly reduced the 5-HT–induced Ca response, compared with no pretreatment, in the absence of VPA (Fig. 2a; t [df 4] = 10.682, p < 0.001, n = 5, 44.8% of Ca increase without PMA). In the presence of PMA, varying VPA concentrations had no effect on the Ca response (Fig. 2a; F3,12 = 0.155, p = 0.929, n = 4). In other words, pretreatment with PMA reversed the inhibitory effect of VPA on the 5-HT–induced Ca response. There was a significant interaction between the effect of VPA and the presence of PMA on the Ca response (Fig. 2a; F3,16 = 4.495, p = 0.0180, n = 5). To evaluate the dose-dependent effect of VPA on the inhibition of 5-HT–induced Ca response by PMA, we calculated percent inhibition of the Ca response by PMA, which showed Ca increase in the presence of PMA / in the absence of PMA × 100%

Table 1: Effects of valproate on 5-HT–induced intraplatelet Ca mobilization

<table>
<thead>
<tr>
<th>VPA, µg/mL</th>
<th>Effect; mean (and SEM)</th>
<th>Increase, nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>55.3 (1.9)</td>
<td>104.8 (5.1)</td>
</tr>
<tr>
<td>10</td>
<td>55.3 (1.6)</td>
<td>98.7 (6.7)</td>
</tr>
<tr>
<td>50</td>
<td>54.7 (1.5)</td>
<td>92.4 (5.9)*</td>
</tr>
<tr>
<td>100</td>
<td>52.7 (2.1)</td>
<td>84.3 (4.8)†</td>
</tr>
<tr>
<td>1000</td>
<td>55.9 (1.8)</td>
<td>42.7 (5.4)†</td>
</tr>
</tbody>
</table>

VPA = valproate.

n = 13

*p < 0.05 compared with group without VPA.

†p < 0.01 compared with group without VPA.

**Effects of VPA on 5-HT–induced Ca response with a PKC stimulator**

The pretreatment with 1 nM PMA significantly reduced the 5-HT–induced Ca response, compared with no pretreatment, in the absence of VPA (Fig. 2a; t [df 4] = 10.682, p < 0.001, n = 5, 44.8% of Ca increase without PMA). In the presence of PMA, varying VPA concentrations had no effect on the Ca response (Fig. 2a; F3,12 = 0.155, p = 0.929, n = 4). In other words, pretreatment with PMA reversed the inhibitory effect of VPA on the 5-HT–induced Ca response. There was a significant interaction between the effect of VPA and the presence of PMA on the Ca response (Fig. 2a; F3,12 = 1.904, p = 0.18). In other words, pretreatment with PMA reversed the inhibitory effect of VPA on the 5-HT–induced Ca response. There was a significant interaction between the effect of VPA and the presence of PMA on the Ca response (Fig. 2a; F3,12 = 0.155, p = 0.929, n = 4). To evaluate the dose-dependent effect of VPA on the inhibition of 5-HT–induced Ca response by PMA, we calculated percent inhibition of the Ca response by PMA, which showed Ca increase in the presence of PMA / in the absence of PMA × 100%

![Fig. 1: Effect of valproate (VPA) on 5-hydroxytryptamine (HT)-induced calcium (Ca) increase in the presence of W-7. Values are the mean and standard error of the mean. There was no significant interaction between the effect of VPA and W-7 on 5-HT–induced Ca response (F3,11 = 0.155, p = 0.929, n = 4).](image1)

![Fig. 2: Effect of valproate (VPA) on 5-hydroxytryptamine (HT)–induced calcium (Ca) increase in the presence of PMA (A). Values are the mean and standard error of the mean. There was a significant interaction between the effect of VPA and phorbol 12-myristate 13-acetate (PMA) on 5-HT–induced Ca response (F3,16 = 4.495, p = 0.018, n = 5). Effect of VPA on the percent inhibition of the Ca response by PMA (B). VPA at 50 and 100 µg/mL significantly reversed the inhibition of 5-HT–induced Ca response by PMA (F3,16 = 8.265, p = 0.0015, n = 5; p < 0.05 versus without VPA).](image2)
VPA at 50 and 100 µg/mL significantly reversed the inhibition of 5-HT–induced Ca response by PMA ($F_{3,16} = 8.265, p = 0.0015, n = 5; p < 0.05$ v. without VPA).

**Effects of VPA on 5-HT–induced Ca response with PKC inhibitors**

No remarkable change in the 5-HT–induced Ca increase was observed when pretreated with 10 nM staurosporine (Fig. 3a; $t$ (df 4) = 1.532, $p = 0.20$, $n = 5$) or 500 nM bisindolylmaleimide II (Fig. 4a; $t$ (df 4) = 2.161, $p = 0.10$, $n = 5$) in the absence of VPA. There was a significant interaction between the effect of VPA and the presence of staurosporine on the Ca response (Fig. 3a; $F_{3,16} = 5.246, p = 0.0103, n = 5$). VPA at 100 µg/mL significantly increased the percent inhibition of the 5-HT–induced Ca response by staurosporine (Fig. 3b; $F_{3,16} = 6.156, p = 0.0055, n = 5; p < 0.05$ v. without VPA). Similar results were obtained for more specific PKC inhibitor, bisindolylmaleimide II. A significant interaction was observed between the effect of VPA and the presence of bisindolylmaleimide II on the Ca response (Fig. 4a; $F_{3,16} = 3.260, p = 0.0390, n = 5$). VPA at 100 µg/mL significantly increased the percent inhibition of the Ca response by bisindolylmaleimide II (Fig. 4b; $F_{3,16} = 8.016, p = 0.0017, n = 5; p < 0.05$ v. without VPA).

**Discussion**

In the present study, we reconfirmed our previous finding.17
that the therapeutic concentration of VPA inhibited the 5-HT–induced intraplatelet Ca response in a concentration-dependent manner without affecting basal concentration and exerted its effect for a short time (30 min). Although therapeutic concentration of VPA for bipolar disorders has not been established, some investigators suggest VPA could be efficacious at the serum concentration range of 50–100 µg/mL in patients with acute mania. This acute effect of VPA on the 5-HT–induced Ca response might be involved in the antimanic properties in the treatment of bipolar disorders, which are obtained several days after VPA administration.

The 5-HT–induced Ca response was significantly enhanced by pretreatment with 30 µM W-7, which has a specific inhibitory effect on calmodulin. Although the mechanisms by which calmodulin antagonist increase the Ca mobilization have not been fully clarified, Ohkubo and others showed similar results: W-7 enhanced thromboxane A2-mediated Ca mobilization in rabbit platelets. In the present study, although the enhanced Ca response to 5-HT in the presence of W-7 was decreased when incubated in the presence of 50 or 100 µg/mL VPA, there was no significant interaction between the effect of VPA and the presence of W-7, suggesting that the acute effect of VPA on Ca response may be independent of a calmodulin system, in contrast with the effect of lithium. However, it is reported that VPA inhibits the cyclooxygenase pathway and the synthesis of thromboxane A2 in platelets and brains. Thus, it is possible that the interaction between W-7 and VPA on the Ca response may be cancelled by the mechanisms, via arachidonate cascade.

PMA (1 nM) alone attenuated the 5-HT–induced Ca response, consistent with a previous report showing that thrombin-induced intracellular Ca increase was suppressed in PMA-treated human platelets through the accumulation of the PI-P and the reduction of IP3. These findings indicated that PKC would operate a negative feedback on the degeneration of inositol phospholipids. Therefore, our results might also might be owing to the negative feedback by PMA. In addition, pretreatment of PMA reversed the inhibitory effect of VPA on the 5-HT–induced Ca response, contrary to producing the additional inhibition of Ca response. That is, the degree of the reduced Ca response to 5-HT induced by a PKC activator was diminished by preincubation with VPA in a dose-dependent manner, whereas VPA itself significantly inhibited the 5-HT–induced Ca response. This indicates that VPA may have a counterbalancing effect on the excessive activation of PKC. However, the nonspecific PKC inhibitor staurosporine (10 nM) and the specific PKC inhibitor bisindolylmaleimide II (500 nM) did not modify the 5-HT–induced Ca response, congruent with the previous observation with another PKC inhibitor H-7. Regarding the effect of staurosporine on PI signalling, Watson and colleagues demonstrated that staurosporine (1 µM) had no effect on the formation of phosphatidic acid and inositol phosphates induced by thrombin in human platelets.

These findings strongly suggest that, in contrast with PMA, the inhibition of PKC either by staurosporine or bisindolylmaleimide II is not related to the receptor-mediated PI signalling leading to Ca mobilization. However, as with the combination of VPA and PMA, the pretreatment of staurosporine or bisindolylmaleimide II, which did not modify the Ca response alone, reversed the inhibitory effect of 100 µg/mL VPA on the 5-HT–induced Ca response. The interaction between the effect of VPA and the presence of PKC inhibitor suggests that the action of VPA on 5-HT–stimulated Ca mobilization is affected at least by PKC inhibition.

Taken together, the therapeutically effective dose of VPA attenuates the Ca response in an acute phase and may modulate PKC systems rather than calmodulin systems. However, the association between these 2 phenomena has not determined in this study. In light of the relation between treatment response to mood stabilizers and the Ca response, we reported in a longitudinal follow-up study that the patients with depression with enhanced Ca response to 5-HT exhibited a good response to mood stabilizers such as VPA and lithium in bipolar disorders. Therefore, further investigations, including an examination of the effect of VPA on the Ca response in platelets of patients with bipolar disorder, are needed to elucidate whether the mechanism of the acute effect of VPA on Ca mobilization is related to therapeutic actions as a mood stabilizer.

In conclusion, we demonstrated that VPA at clinical efficacious concentration itself reduced the 5-HT–induced intraplatelet Ca increase in normal subjects. Both a PKC activator and PKC inhibitors attenuated this inhibitory effect of VPA, while the enhanced effect of a calmodulin antagonist on the Ca response was not affected by VPA. The present findings suggest that the mechanism of the rapid action of VPA may be partly related to a PKC pathway, although there is a possibility that some other mechanisms may be involved.

Acknowledgements: This work was partly supported by grants-in-aid for Soul and diseases-of-the-nervous-system research (T. Koyama) from the Japanese Ministry of Health, Labor and Welfare, and for Scientific Research No. 17591192 (I. Kusumi) from the Japanese Ministry of Education, Culture, Sports, Science and Technology.

Competing interests: None declared.

Contributors: Drs. Kusumi, Koyama and Suzuki designed the study. Drs. Akimoto and Suzuki participated in the acquisition of data, which Drs. Akimoto, Kusumi and Masui analyzed. Drs. Akimoto and Kusumi wrote the article, and Drs. Kusumi, Masui, Koyama and Suzuki critically reviewed it. All authors gave approval for the final version of the article to be published.

References

1. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways; molecular targets for lithium’s actions. Arch Gen Psychiatry 1995;52: 531-43.
5. Okayo Y, Kagaya A, Shinnou H. Serotonin-induced platelet cal-

J Psychiatry Neurosci 2007;32(1)